From the Department of Health Care Policy, Harvard Medical School (W.Z., M.E.C., N.M.), RAND (T.B.S.), and the Department of Medicine, Brigham and Women's Hospital (T.B.S.) - all in Boston.
N Engl J Med. 2019 Mar 14;380(11):1043-1052. doi: 10.1056/NEJMsa1807069.
The United States is undergoing a crippling opioid epidemic, spurred in part by overuse of prescription opioids by adults 25 to 64 years of age. Of concern are long-duration and high-dose initial prescriptions, which place the patients and their friends and relatives at heightened risk for long-term opioid use, misuse, overdose, and death.
We estimated the incidence of initial opioid prescriptions in each month between July 2012 and December 2017 using administrative-claims data from across the United States (accessed through Blue Cross-Blue Shield [BCBS] Axis); monthly incidence was estimated as the percentage of enrollees who received an initial opioid prescription among those who had not used opioids (i.e., no opioid prescription or a diagnosis of opioid use disorder in the 6 months before a given month). We then estimated the percentage of enrollees initiating opioid therapy who received a long-duration or high-dose initial opioid prescription in each month during this period. We also calculated the number of providers who initiated opioid therapy in any patient who had not used opioids in each month and examined monthly trends in the duration and dose of initial opioid prescriptions in prescriber and patient subgroups. Our study sample included 63,817,512 enrollees who had not used opioids (mean, 15,897,673 per month).
The monthly incidence of initial opioid prescriptions among enrollees who had not used opioids declined by 54%, from 1.63% in July 2012 to 0.75% in December 2017. This decline was accompanied by a decreasing number of providers (from 114,043 in July 2012 to 80,462 in December 2017) who initiated opioid therapy in any patient who had not used opioids. Nonetheless, among the shrinking subgroup of physicians who initiated opioid therapy in such patients, high-risk prescribing (i.e., prescriptions for more than a 3-day supply or for a dose of 50 morphine milligram equivalents per day or higher) persisted at a monthly rate of 115,378 prescriptions per 15,897,673 enrollees who had not used opioids.
As the opioid crisis progressed between July 2012 and December 2017, many providers stopped initiating opioid therapy. Although the number of initial opioid prescriptions declined, a subgroup of providers continued to write high-risk initial opioid prescriptions. (Funded by the National Institute on Aging and a gift from Owen and Linda Robinson.).
美国正经历一场严重的阿片类药物泛滥危机,部分原因是 25 至 64 岁成年人过度使用处方类阿片药物。令人担忧的是,长期、大剂量的初始处方,使患者及其亲友面临长期使用、滥用、过量用药和死亡的风险。
我们使用全美范围内的行政索赔数据(通过蓝十字蓝盾协会[BCBS]Axis 获得),估算了 2012 年 7 月至 2017 年 12 月期间每月初始阿片类药物处方的发生率;每月发生率的估算方法为,在未使用过阿片类药物的参保人中(即当月前 6 个月内无阿片类药物处方或阿片类药物使用障碍诊断),接受初始阿片类药物处方的参保人所占百分比。然后,我们估算了在此期间,每月开始阿片类药物治疗的参保人中,有多少人接受了长期或大剂量的初始阿片类药物处方。我们还计算了在每个月中,任何一个未使用过阿片类药物的患者中,有多少个提供者开始了阿片类药物治疗,并研究了在处方者和患者亚组中,初始阿片类药物处方持续时间和剂量的月度趋势。我们的研究样本包括 63817512 名未使用过阿片类药物的参保人(平均每月 15897673 人)。
在未使用过阿片类药物的参保人中,初始阿片类药物处方的每月发生率下降了 54%,从 2012 年 7 月的 1.63%降至 2017 年 12 月的 0.75%。这一下降伴随着提供者数量的减少(从 2012 年 7 月的 114043 人减少到 2017 年 12 月的 80462 人),这些提供者在任何未使用过阿片类药物的患者中都开始了阿片类药物治疗。尽管如此,在开始为这些患者开阿片类药物的缩小的医生亚组中,高风险处方(即开具超过 3 天供应量或开具 50 毫克吗啡当量/天或更高剂量的处方)的比例仍保持在每月每 15897673 名未使用过阿片类药物的参保人 115378 份的水平。
自 2012 年 7 月至 2017 年 12 月阿片类药物危机期间,许多提供者停止了阿片类药物治疗。尽管初始阿片类药物处方的数量有所下降,但一部分提供者继续开出高风险的初始阿片类药物处方。(由国家老龄化研究所资助,并得到 Owen 和 Linda Robinson 的捐赠。)